AstraZeneca
AstraZeneca’s listing rejig spells long-term danger for London | Nils Pratley
September 29, 2025One reaction to AstraZeneca’s listing rejig is relief. The big worry was that the second largest company on the London Stock Exchange would skip off entirely to New York, keeping only a secondary listing in the UK as a face-saver for the government. That, fortunately, is not the plan. Instead, the pharma giant is upgrading […]
Read More